Entities

Tiffany Van Beneden is published in PMV’s current public directory as Management assistant. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Tim Lievens is published in PMV’s current public directory as Head of Corporate Loans. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Tim Moonens is published in PMV’s current public directory as Head of ICT. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Tim Neven is published in PMV’s current public directory as Financial analyst. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Timon Terrens is published in PMV’s current public directory as Senior Legal Counsel. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Timothy Look is published in PMV’s current public directory as ICT Operations Officer. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Tine Vandenbussche is published in PMV’s current public directory as Executive Committee Member - Operations. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Tobias Wilms is published in PMV’s current public directory as Investeringsmanager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred. Tobias Wilms is identified in the current Belgian company registry as a permanent representative of a corporate director of Theodorus IV SA. This governance role is distinct from investment-team employment or personal investment.

Tom Biesemans is published in PMV’s current public directory as Senior investment manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Tom De Bosschere is published in PMV’s current public directory as Investment Director. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Tom De Keersmaecker is published in PMV’s current public directory as Investment Support Officer. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Tom Leemans is published in PMV’s current public directory as Head of Accounting. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Graham Pierpoint is listed by Parkinson’s UK as Graham Pierpoint. Own published biography: Graham Pierpoint I was delighted to become the Parkinson's UK Trustee from Northern Ireland in 2025. I have been Chair of a local Parkinson's support group for 9 years. My wife is the group secretary and her mother had Parkinson's. My motivation comes from witnessing the care and passion of the local volunteers and the significant role they play in helping and supporting people affected by Parkinson's. I hope to use the experience of my involvement within the Parkinson's community in my role as Trustee. Before I retired, I worked in the pension scheme of a large organisation. My interests include travelling, gardening, playing golf and spending time with my grandchildren.

Sven Lenaerts is published in PMV’s current public directory as BI Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Thijs Verbeurgt is published in PMV’s current public directory as Board Director. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Thomas Beke is published in PMV’s current public directory as Investment manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Thomas Berger is published in PMV’s current public directory as Investment manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Thomas Marrecau is published in PMV’s current public directory as Investment analyst. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Steven De Schepper is published in PMV’s current public directory as Investment Director Transport & Digital Infrastructure. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Steven Lassat is published in PMV’s current public directory as Fund manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Steven Oosterlynck is published in PMV’s current public directory as SPV Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Elaine Evans is listed by Parkinson’s UK as Elaine Evans. Own published biography: Elaine Evans I was diagnosed with Parkinson's in 2000, when I was 47. I then became a trustee for Wales in 2020. I’m delighted to have the opportunity to share my Parkinson’s journey in a positive way, and love to hear other people’s experiences. Before retiring in 2015, my career was in local government. After qualifying as a social worker, I progressed to working as a general manager in health and social care. Now, I live in Rhos on Sea in North Wales where I’m a member of the Parkinson’s UK Llandudno and District Support Group . I enjoy keeping fit, and whatever the weather I walk daily using Nordic poles. Watch Elaine's chat with Gary Shaughnessy (our Chair) on YouTube to find out more about her interests, background and why she became a Parkinson's UK trustee.

Simon Gheysen is published in PMV’s current public directory as Board Director. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Smitha Van den Acker is published in PMV’s current public directory as Paralegal. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Sofie Bijnens is published in PMV’s current public directory as Investment manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Sophie De Bie is published in PMV’s current public directory as Management Assistant. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Sophie Manigart is published in PMV’s current public directory as Board Director. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Stephanie Evenepoel is published in PMV’s current public directory as ESG Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Steven Adons is published in PMV’s current public directory as Investment Director Real Estate. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Brian Carson is listed by Parkinson’s UK as Brian Carson. Own published biography: Brian Carson I am delighted to join the Board of Trustees for Parkinson’s UK and look forward to supporting the charity in helping to improve the lives of people with Parkinson’s and their families, friends and carers. I have been volunteering for some time as part of the Glasgow Young Onset Parkinson’s Support Group and also set up and run a weekly table tennis session for people with Parkinson’s. As a volunteer, I have already worked closely with Parkinson’s UK, local health providers and other volunteers on various projects delivering support and services. I look forward to bringing my experience and connections, across the Parkinson’s community, to my role on the Board of Trustees. Brian retired 3 years ago from a career in engineering, where he designed, built and tested complex warships for the Royal Navy. He was diagnosed with Parkinson’s in 2017.

Robin Mees is published in PMV’s current public directory as Investment Director. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Ronny Leloup is published in PMV’s current public directory as Internal auditor. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Ruth Van Walle is published in PMV’s current public directory as Senior Legal counsel. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Sanne Vergaelen is published in PMV’s current public directory as Supervisor Investment Support. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Sara Vanneste is published in PMV’s current public directory as Investment manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Sébastien Durbecq is published in PMV’s current public directory as Functioneel Analyst. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Sebastien Tobback is published in PMV’s current public directory as Investment manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Simon Ceulemans is published in PMV’s current public directory as Senior Legal Counsel. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Gary Shaughnessy is listed by Parkinson’s UK as Chair (published incumbent; October 2026 handover pending exact date). Own published biography: Gary Shaughnessy CBE (Chair) I was diagnosed with Parkinson's in 2015. I became a trustee of Parkinson’s UK in 2018, and then Chair of the Board in October 2019. I’m passionate about using my voice and experience to raise awareness of Parkinson’s and improve life for people living with the condition. My career was in the insurance and financial services industry. I stepped down from my role as CEO of Europe, Middle East and Africa for Zurich Insurance in 2018. I wanted to spend more time with my family, on non-executive roles and my fitness. Exercise helps me manage my Parkinson’s symptoms. I enjoy combining sport with community engagement to raise funds and awareness for the charity. This has included wing walking, abseiling and running marathons. If you have any thoughts or ideas on how we can continue to support people with Parkinson’s, I’d love to hear from you. You can reach me via email [email protected] or on Twitter @gshaug7741. June2026 own announcement schedules chair succession inOctober2026; no exact completed handoverday is established.

Pieter-Jan D’Haese is published in PMV’s current public directory as Investment manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Pieter Sablon is published in PMV’s current public directory as Investment Director Transport & Digital Infrastructure. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Quinten Depré is published in PMV’s current public directory as Investment Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Raf Suys is published in PMV’s current public directory as Board Director. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Renate Verhoeven is published in PMV’s current public directory as Supervisor PMV-Standaardwaarborgen. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Renaud Kayaert is published in PMV’s current public directory as Auditor. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Rik Truijen is published in PMV’s current public directory as Senior Investment Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Rindert Missiaen is published in PMV’s current public directory as Investeringsmanager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Roald Borré is published in PMV’s current public directory as Executive Committee Member - Equity Investments. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

David Newbold is listed by Parkinson’s UK as Director of Community. Own published biography: "It is an utter privilege to work for Parkinson's UK, an organisation that has provided so much support to my dad, and indeed to my entire family, after he was diagnosed with early onset Parkinson’s. Having early access to advice, information and support made a huge difference to my family. I am committed to ensuring that more people know, that whatever your journey is with Parkinson's, you are not alone and a whole community of support is here for you. "Before joining Parkinson's UK, I led services at a large sight loss charity focussed on growing support for people at point of diagnosis and peer to peer support. "Outside of work, I volunteer with a local children's group, support disabled job seekers, and love nothing more than time with my family and friends and the occasional trip to the gym!"

Pepijn Wuytack is published in PMV’s current public directory as Kredietanalist PMV-Standaardleningen. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Peter Doms is published in PMV’s current public directory as Compliance manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Peter Sleeckx is published in PMV’s current public directory as Head of PMV-Standaardwaarborgen. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Peter Verhaeghe is published in PMV’s current public directory as Board Director. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Peter Vos is published in PMV’s current public directory as Senior Investment Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Petra Geerdens is published in PMV’s current public directory as Head of PMV-Standaardleningen Back Office. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Piet Renson is published in PMV’s current public directory as Investment Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Pieter Ceusters is published in PMV’s current public directory as Senior investment manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Pieter Hensen is published in PMV’s current public directory as Senior investment manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Adrian Blair is listed by Parkinson’s UK as Chief People Officer. Own published biography: "I am delighted to have joined Parkinson's UK in February 2024. I have seen the impact of this condition on not just the individual but also their family. It is a privilege to work in an organisation that is dedicated to supporting people affected by Parkinson's, and ultimately searching to find a cure. "With my colleagues in the People and Culture team, we support everyone who comes to work in Parkinson's UK, whether they are employed in the charity or volunteering their time and skills to support our work. We look after the full employee lifecycle from advertising new opportunities through to that moment when colleagues retire or move to another organisation. We are here to help make Parkinson's UK a great place to work. "I started my career in the private and public sectors before moving to charity, where I have worked in international development, health and social care. I have a passion for identifying and leading change and have led large-scale business transformation and information and computer technology (ICT) programmes, which have involved cultural change. Whilst I originally qualified in computing science and am a qualified PRINCE2 and Managing Successful Programmes (MSP) practitioner, I am a Chartered Fellow of CIPD and hold a post-grad in psychology of change and organisational development.

Michel Casselman is published in PMV’s current public directory as General Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Michiel Nagels is published in PMV’s current public directory as Compliance Officer. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Nathalie Sierens is published in PMV’s current public directory as Investment Director Corporate Loans. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Nicholas Hartnett is published in PMV’s current public directory as Investment Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Nick Wouters is published in PMV’s current public directory as Business Application Support Officer. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Oliver Vander Cruysse is published in PMV’s current public directory as Senior Investment Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Malika Tsagaraeva is published in PMV’s current public directory as Management Assistant. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Marc Neirinckx is published in PMV’s current public directory as Senior Investment Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Marie Delbeke is published in PMV’s current public directory as Head of Unit Expert. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Matthieu van den Bogaert is published in PMV’s current public directory as Communications Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Mauro Do Prado is published in PMV’s current public directory as Facilitair Medewerker. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Maxime Van Peel is published in PMV’s current public directory as Head of RK Sustainable Industries. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Michaël Raes is published in PMV’s current public directory as Senior Investment Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Paul Jackson-Clark is listed by Parkinson’s UK as Director of Fundraising and Experience. Own published biography: "I've been lucky to have worked in the UK charity sector for 30 years and at Parkinson's UK since 2009. "I am inspired, fascinated and energised by people's tireless and selfless capacity to give money and time to charities, just like ours, for the benefit of others. "When I am not working, I like to cycle, cook and laugh with family and friends."

David Dexter is listed by Parkinson’s UK as Director of Research. Own published biography: "I've held various positions over my almost 40-year career, including Scientific Director of the Parkinson’s UK Brain Bank and Deputy Head of the Division of Brain Sciences at Imperial College London. At Imperial, I had a research team looking into the causes and developing new treatments for Parkinson's. And in 2017 I joined Parkinson's UK as the Associate Director of Research. "My relationship with the charity started when they funded my PhD in 1985, so I’m very proud to now be stepping into a leadership role which oversees the research grants programme and portfolio of active projects. The research that’s happening in this area is not only building a pipeline of discoveries to fuel the Parkinson’s UK drug development and discovery work, it’s also helping us better understand the condition, how it develops, how we can monitor it and how symptoms can be managed in other ways, including non-drug approaches. All of this is vital work. "In my new role as Research Director, I will also oversee research communications and involvement, making sure that the views of people with Parkinson’s are taken into account in our work and that of others. Additionally, we must maximise the potential opportunities for people with Parkinson’s to take part in research. It’s an area that I’m passionate about as it’s vital to shaping the future of research."

Luc Van Rooijen is published in PMV’s current public directory as Fund manager; PMV Fund Management Fund Manager (related manager). This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Maarten Bettens is published in PMV’s current public directory as Senior Investment Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Malika Kurbanova is published in PMV’s current public directory as Boekhouder. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Lieven De Jonge is published in PMV’s current public directory as Investment Director Equity Investments. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Len Wachsmuth is published in PMV’s current public directory as Investment analyst. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Lennert Thomas is published in PMV’s current public directory as Senior Investment Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Lien Haesaert is published in PMV’s current public directory as Dossierbeheerder. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Lien Vannieuwenhove is published in PMV’s current public directory as Investment Support Officer. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Lieselot Versyck is published in PMV’s current public directory as Senior investment manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Lieselotte De Troy is published in PMV’s current public directory as Dossierbeheerder. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Koen Heindryckx is published in PMV’s current public directory as Investment Director. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Koen Kennis is published in PMV’s current public directory as Board Director. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Koen Lebegge is published in PMV’s current public directory as Government commissioner. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Kristel Raes is published in PMV’s current public directory as Supervisor PMV-Standaardleningen. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Kristien Smedts is published in PMV’s current public directory as Board Director. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Kristina Loguinova is published in PMV’s current public directory as Head of Compliance. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Kylie Vandecauter is published in PMV’s current public directory as Dossierbeheerder. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Léandre Kabuya is published in PMV’s current public directory as Dossierbeheerder. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Jolien Van de Velde is published in PMV’s current public directory as Reporting Officer Infrastructure. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Julie Bockstal is published in PMV’s current public directory as Junior Credit Analyst. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Karen Thiers is published in PMV’s current public directory as HR consultant. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Karen Van Campenhout is published in PMV’s current public directory as Dossierbeheerder. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Karin Vervloet is published in PMV’s current public directory as Executive assistant. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Karolien Phlips is published in PMV’s current public directory as Senior Legal counsel. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Kathy Thijssen is published in PMV’s current public directory as Senior Accountant. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Katrien De Brauwer is published in PMV’s current public directory as Investment Support Officer. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Kelly Niesing is published in PMV’s current public directory as Management assistant. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Kenneth Vanhecke is published in PMV’s current public directory as Corporate Relations Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Kenneth Wils is published in PMV’s current public directory as Head of Life Sciences & Care. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Kiana Buttiens is published in PMV’s current public directory as Investeringsanalist. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Kjell Verley is published in PMV’s current public directory as Credit analyst. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Koen De Pelsemaeker is published in PMV’s current public directory as Head of unit Program Management. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Jeroen Vergote is published in PMV’s current public directory as Investment Director. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Jessica Bouillon is published in PMV’s current public directory as Investment Support Officer. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Jim Priem is published in PMV’s current public directory as Investeringsmanager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Joachim Exter is published in PMV’s current public directory as Fund administrator. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Joeri Covers is published in PMV’s current public directory as Facility manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Johan Keppens is published in PMV’s current public directory as Investment Director Equity Investments. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Johan Laes is published in PMV’s current public directory as File manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Johan Reynaert is published in PMV’s current public directory as EU Laison officer. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Isaak Boone is published in PMV’s current public directory as Investment manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Isabelle De Wit is published in PMV’s current public directory as Head of PMV-Standaardleningen Front Office. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Isabelle Gierts is published in PMV’s current public directory as Senior Investment Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Issandra Tursini is published in PMV’s current public directory as Investment Support Officer. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Jan Hollez is published in PMV’s current public directory as Board Director. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Jan Lebon is published in PMV’s current public directory as Auditor. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Jan Marien is published in PMV’s current public directory as Senior Legal counsel. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Jason-Louise Graham is published in PMV’s current public directory as Investeringsmanager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Jean De Vreeze is published in PMV’s current public directory as Dossierbeheerder. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Hafida Ajouaou is published in PMV’s current public directory as Dossierbeheerder. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Hava Izci is published in PMV’s current public directory as Investeringsanalist. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Hava Kurbanova is published in PMV’s current public directory as Management Assistant. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Hayal Karahisarli is published in PMV’s current public directory as Accountant. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Heleen De Bock is published in PMV’s current public directory as Senior Legal Counsel. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Hendrik-Jan Van Der Gucht is published in PMV’s current public directory as Senior Investment Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Hilde Van Nieuwenhuyzen is published in PMV’s current public directory as Management assistant. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Gregory Denturck is published in PMV’s current public directory as BI manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Greta Leeten is published in PMV’s current public directory as Auditor. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Geert Ost is published in PMV’s current public directory as Paralegal. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Geert Schoukens is published in PMV’s current public directory as Investment Director. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Geertrui De Bruyn is published in PMV’s current public directory as Investment Support Officer. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Gieljan Van de Velde is published in PMV’s current public directory as Senior Legal Counsel. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Godfried Ampe is published in PMV’s current public directory as Senior Legal Counsel. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Gorik Noynaert is published in PMV’s current public directory as SPV Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Florian Vanderveken is published in PMV’s current public directory as Investment Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Frank Kindt is published in PMV’s current public directory as Head of Communications. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Geert Diericx is published in PMV’s current public directory as Executive Committee Member - Finance. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Geert Glorieux is published in PMV’s current public directory as Facility employee. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Geert Jacobs is published in PMV’s current public directory as Head of Transport & Digital infrastructure; PMV Fund Management affiliation (related manager). This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Geert Loyens is published in PMV’s current public directory as Dossierbeheerder. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Geert Mertens is published in PMV’s current public directory as SPV manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Capsida Biotherapeutics Inc. is a Thousand Oaks, California biotechnology company developing engineered adeno-associated virus capsids and targeted genetic medicines for neurological and ocular diseases. Originating in Viviana Gradinaru’s Caltech laboratory, its platform combines high-throughput capsid screening, biological-barrier targeting, therapeutic cargo development and gene-therapy manufacturing. It researches intravenous brain delivery and less invasive intravitreal/suprachoroidal ocular delivery. As of its May2026 primary update, Capsida closed the CAP-002 SYNRGY STXBP1 developmental/epileptic encephalopathy trial following the first treated patient’s September2025 death from cerebral edema; the underlying cause remained unresolved. It also announced closure of its CAP-003 Parkinson’s/GBA trial, in which no patients were dosed. Its next-generation RECK-receptor CNS capsid work and ocular programs remain preclinical research, not approved medicines or proven human efficacy. The current directory names Mina Kim executive chair, Romuald Corbau chief scientific officer, Amar Duvvur COO/CFO and co-founder Nicholas Flytzanis research/innovation chief. Current board members and separately qualified founders/historical2025 affiliations are included. Funding includes a50MSeriesA backed by Versant and Westlake, confirmed10MAbbVie equity, and12MNEURO.VC convertible-note financing. Commercial collaborations with AbbVie, Prevail/Lilly, CRISPR and Kate are distinguished from equity; upfront licensing payments, possible future investments, milestones, royalties and cumulative funding totals are not treated as additional closed priced rounds.

Amar Duvvur leads Capsida operations and finance. He previously served in finance leadership at Acelyrin, Sanford Burnham Prebys, AbbVie, CareFusion, Tyco and General Motors, with experience in IPOs and acquisitions. He studied management at Northwestern and engineering at UC Irvine.

Beth Seidenberg is a Capsida board director and founding managing director of Westlake BioPartners. She co-founded the investment platform in 2018 after biotechnology investing at Kleiner Perkins and drug-development leadership at Amgen, Bristol-Myers Squibb and Merck. She studied at Barnard and earned a medical degree at the University of Miami, followed by postgraduate training at NIH and Johns Hopkins. Her investing spans company incubation and multiple therapeutic modalities.

Celeste Stephany is named by Capsida in its May12,2026 corporate update as executive director of CNS and ophthalmology preclinical research and presenter of engineered ocular AAV data at ASGCT. Further individual biography and name-bound portrait were not published in the reviewed sources.

Clare Ozawa is a Capsida board director and Versant Ventures managing director. Her career includes company creation and operational leadership at Inception Sciences and strategic work in the Novartis CEO office. She trained in biological sciences and neuroscience at Stanford. Clare Ozawa is Versant Ventures’ current Managing Director. Company builder with Inception operational experience, prior Novartis CEO-office strategy and McKinsey consulting. Stanford-trained biological scientist and neuroscience PhD.

Filip Lacquet is published in PMV’s current public directory as Executive Committee Member - Corporate Finance. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Hari Acharya is named by Capsida in its May12,2026 corporate update as executive director of process and analytical development and presenter of engineered AAV manufacturing-process research at ASGCT. Further individual biography and name-bound portrait were not published in the reviewed sources.

Mina Kim is Capsida’s executive chair. She previously led Acelyrin as CEO and chief legal/administrative officer and held corporate-development and legal leadership at Zymergen and Atara. She holds a Harvard JD and Dartmouth history BA.

Nicholas Flytzanis co-founded Capsida and leads research and innovation. He previously directed Caltech’s CLOVER research center and studied AAV engineering, optogenetics, imaging and neurological gene therapy. He holds an MIT biology bachelor’s degree and Caltech biology doctorate.

Nick Goeden co-founded Capsida with Nicholas Flytzanis, translating AAV engineering from Viviana Gradinaru’s Caltech laboratory. The current company history identifies him as the postdoctoral researcher who helped develop the platform. Its May2025 deck additionally lists him as chief technology officer; that operational title is treated as dated rather than confirmed current.

Romuald Corbau is Capsida’s chief scientific officer, appointed in2026. His gene-therapy career includes scientific leadership at Adverum, GenEdit, Freeline and Spark, following drug-discovery roles at CISTIM and Pfizer. He earned biochemistry qualifications and a doctorate at Lille.

Szilárd Kiss is a Capsida board director and retina specialist with ocular gene-therapy and translational-research expertise. His Weill Cornell roles include ophthalmology professor, retina-service chief, research director and clinical-compliance associate dean. He studied at Columbia and trained at Massachusetts Eye and Ear/Harvard.

Viviana Gradinaru is a Caltech neuroscience and biological-engineering professor whose laboratory developed the AAV engineering research underlying Capsida. The company’s May2025 deck identifies her as a founder and board member; the current board directory omits that affiliation, so current board tenure is not inferred.

Ben Clarkson is listed by Parkinson’s UK as Chief Finance and Operating Officer. Own published biography: "I'm delighted to have joined Parkinson's UK as its Chief Finance and Operating Officer because I recognise what an outstanding and ambitious organisation it is, rooted in the needs of the Parkinson's community. My late grandfather, to whom I was very close, lived with Parkinson's towards the end of his life. I saw how it affected him and those around him. "I am motivated to play my part in driving forward Parkinson UK's ambition, drawing on my experiences of helping organisations become fit for the future to have a positive impact for the charity and the people it exists to support."

Barbara Wentzel is Deputy Chair, Supervisory Board at BeiersdorfAG. Member of Supervisory Board since April 2024 Deputy Chairwoman since April 2024 Employee representative. This supervisory governance affiliation is distinct from venture-team employment or a personal investment.

Doris Robben is Supervisory Board Member at BeiersdorfAG. Member of Supervisory Board since April 2024 Employee representative. This supervisory governance affiliation is distinct from venture-team employment or a personal investment.

Frédéric Pflanz is Deputy Chair, Supervisory Board at BeiersdorfAG. Member of Supervisory Board since April 2019 (previously from September 2015 to April 2018) Deputy Chairman since September 2022 Shareholder representative. This supervisory governance affiliation is distinct from venture-team employment or a personal investment.

Jan Koltze is Supervisory Board Member at BeiersdorfAG. Member of Supervisory Board since April 2019 Employee representative. This supervisory governance affiliation is distinct from venture-team employment or a personal investment.

Kirstin Weiland is Supervisory Board Member at BeiersdorfAG. Member of Supervisory Board since April 2019 Employee representative. This supervisory governance affiliation is distinct from venture-team employment or a personal investment.

Olaf Papier is Supervisory Board Member at BeiersdorfAG. Member of Supervisory Board since April 2019 Employee representative. This supervisory governance affiliation is distinct from venture-team employment or a personal investment.

Burcu Andreae-Nehlsen is a member of Beiersdorf’s published corporate leadership. Current own remit: Member of the Executive Committee President Derma & Health Care. This is a corporate leadership role, not inferred direct fund investment committee membership.

Donya-Florence Amer is Supervisory Board Member at BeiersdorfAG. Member of Supervisory Board since April 2024 Shareholder representative. This supervisory governance affiliation is distinct from venture-team employment or a personal investment.

Els Lamberts is published in PMV’s current public directory as Senior Investment Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Elsie Van Nyverseel is published in PMV’s current public directory as Senior Accountant. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Emile Symons is published in PMV’s current public directory as Senior investment Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Eric Van Cauwenbergh is published in PMV’s current public directory as PMV Fund Management Executive Committee Member - Risk & Compliance (related manager). This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Erwin Adriaenssens is published in PMV’s current public directory as Auditor. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Erwin Vrijens is published in PMV’s current public directory as Head of Real Estate. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Evelyne van Wijk is published in PMV’s current public directory as Investment manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Evi Wens is published in PMV’s current public directory as Supervisor PMV-Standaardleningen. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Fanny Lietaer is published in PMV’s current public directory as Management assistant. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Feya Smets is published in PMV’s current public directory as Investment manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Filip Clarisse is published in PMV’s current public directory as Communications manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Filip Goossens is published in PMV’s current public directory as Senior investment manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Gitta Neufang is a member of Beiersdorf’s published corporate leadership. Current own remit: Member of the Executive Committee Chief Research & Development Officer. This is a corporate leadership role, not inferred direct fund investment committee membership.

Hilde Cambier is Supervisory Board Member at BeiersdorfAG. Member of Supervisory Board since April 2024 Employee representative. This supervisory governance affiliation is distinct from venture-team employment or a personal investment.

Hong Chow is Supervisory Board Member at BeiersdorfAG. Member of Supervisory Board since April 2017 Shareholder representative. This supervisory governance affiliation is distinct from venture-team employment or a personal investment.

Michael Frey is a member of Beiersdorf’s published corporate leadership. Current own remit: Member of the Executive Committee Chief Supply Chain Officer (CSCO) Quality Management. This is a corporate leadership role, not inferred direct fund investment committee membership.

Reinhard Pöllath is Chairman, Supervisory Board at BeiersdorfAG. Member of Supervisory Board since May 2002 Chairman since April 2008 Shareholder representative. This supervisory governance affiliation is distinct from venture-team employment or a personal investment.

Uta Kemmerich-Keil is Supervisory Board Member at BeiersdorfAG. Member of Supervisory Board since August 2022 Shareholder representative. This supervisory governance affiliation is distinct from venture-team employment or a personal investment.

Wolfgang Herz is Supervisory Board Member at BeiersdorfAG. Member of Supervisory Board since April 2020 Shareholder representative. This supervisory governance affiliation is distinct from venture-team employment or a personal investment.

Débra Wellekens is published in PMV’s current public directory as Executive assistant. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Didier Detobel is published in PMV’s current public directory as ICT Operations Support Officer. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Dieter Blondeel is published in PMV’s current public directory as Senior Investment Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Dries De Luyck is published in PMV’s current public directory as Functioneel Analist. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Elke Meert is published in PMV’s current public directory as Management assistant. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Elke Van de Walle is published in PMV’s current public directory as Executive Committee Member - Legal Affairs and Audit. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Ellen De Greve is published in PMV’s current public directory as Credit analyst. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Els Debulpaep is published in PMV’s current public directory as Management assistant. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Ramon A. Mirt is a member of Beiersdorf’s published corporate leadership. Current own remit: Member of the Executive Board Emerging Markets (Latin America, Africa, Russia, Asia excl. Greater China). This is a corporate leadership role, not inferred direct fund investment committee membership.

Christophe Behiels is published in PMV’s current public directory as Investment Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Christophe Ost is published in PMV’s current public directory as Project Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Danny Geerinckx is published in PMV’s current public directory as Dossierbeheerder. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Danny Van Roijen is published in PMV’s current public directory as Compliance Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Danny Van Wilder is published in PMV’s current public directory as System engineer. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Dany Vandevelde is published in PMV’s current public directory as Investment Director Equity Investments. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Davy De Nutte is published in PMV’s current public directory as Business Application Support Officer. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Charlotte Dereere is published in PMV’s current public directory as Investeringsmanager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Chiela Moens is published in PMV’s current public directory as Senior investment manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Christel Michiels is published in PMV’s current public directory as Communications manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Christel Mommaerts is published in PMV’s current public directory as Directie-assistente. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Christiaan Beyaert is published in PMV’s current public directory as Senior Accountant. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Nicola D. Lafrentz is a member of Beiersdorf’s published corporate leadership. Current own remit: Member of the Executive Board – Labor Relations Director – Human Resources (Human Resources, General Services & Facility Management). This is a corporate leadership role, not inferred direct fund investment committee membership.

Anouck De Schrijver is published in PMV’s current public directory as Senior investment manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Anthony Van Aerdebrugge is published in PMV’s current public directory as Head of Human Resources. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Anton Debraekeleer is published in PMV’s current public directory as Functioneel Analist. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Astrid Hermann is a member of Beiersdorf’s published corporate leadership. Current own remit: Member of the Executive Board Finance (Finance & Financial Control, Legal & Compliance, Real Estate, Shared Services/BSS GmbH) tesa SE. This is a corporate leadership role, not inferred direct fund investment committee membership.

Audrey De Pauw is published in PMV’s current public directory as Dossierbeheerder. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Aurelie Nowack is published in PMV’s current public directory as Senior investment manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Baptiste Ghesquière is published in PMV’s current public directory as Credit Analyst. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Bart De Taeye is published in PMV’s current public directory as Head of Life Sciences & Care. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred. He has more than 20 years of research experience including 15 years related to drug discovery, and more than 7 years of experience with business development and company creation. Before joining PMV, Bart was active as a Business Development Manager at VIB and as a Search and Evaluation Lead at Cistim focusing on the translation of early-stage research projects. Before that, Bart led a scientific team for more than 10 years as a Project Leader in Drug Discovery at reMYND, where he built a diabetes drug discovery platform, and as a postdoc and assistant professor at Vanderbilt University and Northwestern University. Bart holds a Master's and PhD in Pharmaceutical Sciences from KU Leuven, where he also obtained a Postgraduate degree in Business Economics.

Bertrand Van Regemortel is published in PMV’s current public directory as Investment Director Real Estate. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Brecht Verhaegen is published in PMV’s current public directory as Head of Gigarant. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Carine Carlier is published in PMV’s current public directory as File manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Carine Van Yper is published in PMV’s current public directory as Auditor. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Carolien D’Hauwers is published in PMV’s current public directory as Senior Investment Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Caroline Coppens is published in PMV’s current public directory as Senior Legal Counsel. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Caroline Daskalidès is published in PMV’s current public directory as Senior Legal counsel. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Catherine Geurden is published in PMV’s current public directory as Loan and contract management. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Cato Van Leysen is published in PMV’s current public directory as Investment Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Oswald Barckhahn is a member of Beiersdorf’s published corporate leadership. Current own remit: Member of the Executive Board Europe USA / Canada Luxury (La Prairie, Chantecaille). This is a corporate leadership role, not inferred direct fund investment committee membership.

Participatiemaatschappij Vlaanderen NV, publicly branded PMV, is the Flemish government investment and financing institution, legal Belgian enterprise BE0455.777.660, headquartered at Oude Graanmarkt63 in Brussels. The statutory company was formed July31,1995; the present independent financing platform dates from2001 and celebrated its25-year operating anniversary in2026. PMV combines direct equity, loans, guarantees, fund commitments and strategic infrastructure investments to support companies with a meaningful Flemish connection from startup through international growth. Digital technology, life sciences and care, energy transition, industrial innovation and real estate are among its mandates. General Manager Michel Casselman and Chairman Koen Kennis are confirmed by the current2026 report and own directory. The complete live public directory names213 people across operating, governance, investment, credit, legal, support and specifically labelled related fund-management teams; these213 published affiliations are not a claim that all are direct investment professionals or an employee headcount. The audited2025 report separately counts188 employees. Named original portraits are available for197 of these people;16 lack recoverable original assets. Shared existing people, external board roles and authentic prior portraits are preserved. PMV owns but is legally distinct from PMV Fund Management NV, a separately governed manager. Its current affiliated funds include PMF Infrastructure Fund, EPICo I, EPICo II, Welvaartsfonds and Invest for Jobs, whose management transferred to that subsidiary in June2025. Those are not silently reassigned as parent-managed funds or parent cash investments. Welvaartsfonds completed aEUR167M first commitment close inAugust2021 and reachedEUR205M with a second close announced December1,2021; these completed committed fund sizes differ from paid drawn capital. A government answer separately reports onlyEUR48.8M paid of PMV ownEUR80M commitment. The earlierEUR500M policy target andEUR240M government allocation are not recorded as actual fund closes. PMV also performs fiduciary and operational management of the Flemish government’s Flanders Future Techfund, while separately owned Biotechfonds Vlaanderen and ARKimedes vehicles retain their own legal buyer attribution. The2025 annual report showsEUR4.7646B advised/managed assets and aEUR2.553634455B December5,2025 corporate capital increase connected to Brussels Airport; AUM, balance-sheet subscribed capital and uncalled capital are not new LP fund closes or automatically paid investment tickets. Primary own reMYND evidence confirms an earlier convertible loan and later2018/2021 equity participations; related2022 syndicate members remain unpublished. PMV Pharma is an unrelated US biotechnology company and is left untouched.

Alain Van Hoorebeke is published in PMV’s current public directory as File manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Alex De Ridder is published in PMV’s current public directory as Corporate Relations Officer. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Alexander Van Lil is published in PMV’s current public directory as ESG Consultant. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Amber De Brabander is published in PMV’s current public directory as Senior Legal counsel. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Ana Algueró Nadal is published in PMV’s current public directory as Investment analyst. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Anja Mackelberg is published in PMV’s current public directory as Credit analyst. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Ann Van De Broeck is published in PMV’s current public directory as File manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Anne-Sofie Bogaerts is published in PMV’s current public directory as Investment Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Chunchun Yao is Investment Principal in Beiersdorf’s internal corporate venture capital team. The own current six-person directory confirms this investment/R&D scouting affiliation; no separate external LP management office is inferred.

Janina Zippel is Senior Scientist R&D Startup Scouting in Beiersdorf’s internal corporate venture capital team. The own current six-person directory confirms this investment/R&D scouting affiliation; no separate external LP management office is inferred.

Vincent Warnery is a member of Beiersdorf’s published corporate leadership. Current own remit: Chief Executive Officer Corporate Development & Strategy Internal Audit Supply Chain & Quality Assurance Digital, Tech & AI Research & Development Derma & Health Care Corporate Communication Sustainability Japan. This is a corporate leadership role, not inferred direct fund investment committee membership.

Ascan Voswinckel is Head of Venture Capital in Beiersdorf’s internal corporate venture capital team. The own current six-person directory confirms this investment/R&D scouting affiliation; no separate external LP management office is inferred.

Thomas Raschke is Team Lead R&D Startup Scouting in Beiersdorf’s internal corporate venture capital team. The own current six-person directory confirms this investment/R&D scouting affiliation; no separate external LP management office is inferred.

Oleg Chervonnyi is Investment Principal in Beiersdorf’s internal corporate venture capital team. The own current six-person directory confirms this investment/R&D scouting affiliation; no separate external LP management office is inferred.

Gunes Bozkurt is Director of Venture Investments & Lead of Life Science Investments in Beiersdorf’s internal corporate venture capital team. The own current six-person directory confirms this investment/R&D scouting affiliation; no separate external LP management office is inferred.

Beiersdorf AG is the Hamburg-based skin-care and consumer-products corporation behind NIVEA, Eucerin, La Prairie and other brands, with tesa as a separate business segment. The German stock corporation is registered in Hamburg underHRB1787. Its internal Beiersdorf Venture Capital team, historically called OSCAR&PAUL, invests in life sciences, biotechnology, AI-enabled discovery, sustainability and digital health, with strategic access to corporate R&D and global brands. The current venture site names six investment and R&D scouting professionals and describes early-to-growth investing, primarilySeriesA, minority stakes up to20% and initial0.5–5MEUR tickets; these mandate ranges are not specific company checks. The venture operation is a corporate unit, not asserted as a separate legal investment manager. March31,2026 launch of the second-generation Skin Care Innovation Fund announced100MEUR corporate commitment, not an external LP close, cash already deployed or managerAUM. Its public portfolio includes DeepLife, Turbine, Vincere Biosciences, Rubedo, Cellvie and other deep-technology/healthcare companies. Corporate executive and supervisory roles are separately qualified from direct venture-team employment. Stock repurchases, operating revenue and corporate research budgets are not company cash fundraising.

General director of Groupe Prunay, the French family-owned operating and investment holding group. Current January2026 BODACC notices identify her alongside president PatrickWeil; the group’s own Château legal disclosure independently confirms her management role. Exact appointmentday, education and wider personal career are not published in the reviewed primarysources. No authentic individuallyidentified portrait has been established.

Founder of Groupe Prunay in1993 and current president of the French corporate holding group. He built the group through insurance-services businesses and acquisitions before diversifying into venture investments,building engineering and property. The current group site publishes his authentic portrait; primary2026 French corporate notices independently confirm his presidency. This is the Prunay entrepreneur, not the historian and political-science researcher of the same name.

Groupe Prunay is a French family-owned operating and investment holding group founded in1993 by PatrickWeil and based at Château dePrunay inLouveciennes. It grew through insurance-claims services, construction-insurance management and business acquisitions, then diversified into building engineering, corporate venture investment and property. Its own history records the sale of Eurisk in2015 and Eurexo in2020; those historical subsidiaries are not assumed to remain current portfolio holdings. The current legal corporation is GROUPEPRUNAY, SIREN392372397, registered inVersailles at19Chemin dePrunay,78430Louveciennes. Primary BODACC notices published January27,2026 identify the current SAS form and officers PatrickWeil(President) and CécileGérard(GeneralDirector); July2026 notices confirm the same entity and SAS form. Older own Château legal text still calls it GroupePrunaySA and spells the townVersailles; the current official legal notices supply the correct form and seat, without creating a second firm. Earlier SA board-director lists are historical and do not establish a current board after the SAS change. Its corporate investment programme backs high-growth companies for the long term. Actual AI/deeptech exposure is established by participation in DeepLife’s completed USD10MSeriesA announced December2024, financing AI-powered digitaltwins of human cells and drug-discovery infrastructure. The issuer names GroupePrunay as a participant, not a co-lead; its individual ticket and exact cash-subscribing subsidiary are not published. The whole10M is the company’s syndicate financing, notPrunay’s check or an externallyraised Prunayfund. Its current ownsite publishes an authentic founder/president portrait and an anonymous group photo, but not a named complete staff directory. Only the two source-confirmed current corporate officers are included in this scoped public leadership profile; private team members are not identified from faces or social employee-association lists. CécileGérard’s authentic portrait remains unverified and no groupphoto crop is invented. The website advertises venturecapital and links recruitment to CastleStudio; a studio-brand relationship alone does not establish an independent legal subscriber or justify transferring employees/financing to the parent. No external LP fund, fixed investment budget, committed capital, AUM or completed corporate equity raise is established by ownprimarysources. Registered nominalshare capital and business-sale proceeds are not fundraising. A primary BPCE2010 annual report mentions an arranged EUR12MOBSAR convertible-bond transaction for the group, but does not publish a cashclosing day, subscribing buyers or paid proceeds here; it remains qualified corporate financing research rather than an assumed current VCfund. Transaction-adviser Cambon independently confirms an earlier Prunay investment in Unkle, while secondary claims of broadAfrican mandates or many unrelatedtechholdings are not accepted as company portfolio proof.

Brigitte Boone is identified by the original GFF NV’s official registry as a permanent representative fromJanuary1,2003. The original legal entity was absorbed inDecember2009. This is a historical legal representation rather than a current successor-company employment claim or an inferred personal investment.

François de Vicq de Cumptich is named in the official registry of original GFF NV0461.734.351 as a director fromOctober28,2009. That predecessor ceased through absorption onDecember16,2009. This record uses the ASCII first-name spelling Francois for identity formatting and preserves the accented legal name in evidence; no current appointment to the successor’s board is inferred.

Jozef Briers is named a legal representative of the original Gemma Frisius fund NV in the Belgian registry fromApril11,2003. That entity ceased via merger inDecember2009. The source establishes a dated legal representative affiliation, not a current portfolio-manager title or biographical facts belonging to a namesake.

Luc Weverbergh is named a legal representative of the original GFF NV by its official registry fromJanuary1,2003. The original fund company was absorbed onDecember16,2009. This is a historical legal affiliation and does not imply a present role in the successor company or a personal investment.

Peter Bogaert is named in the original GFF legal entity’s official registry as a permanent representative fromApril11,2003. The predecessor merged into the current NV inDecember2009. This exact historical representation is preserved without an invented current fund-management job, portrait or affiliation to an unrelated namesake.

Anne Roucourt is named a GFF director representing Almanij-KBC in the original university2000 board roster. The source establishes this historical governance affiliation; it does not prove a current role or personal investment. The current NV board and post-merger legal identity are documented separately.

Hans Claes is named a director and advisory committee member representing KU Leuven in its2000 GFF article. A separate1999 university article identifies him as director of KU Leuven Research & Development. This is the historically identified university technology-transfer professional; unrelated same-name people are not merged and a current GFF role is not inferred.

Julien Smets is named a GFF director representing VIV-Fortis in KU Leuven’s original2000 fund article. The source establishes the historical fund-board identity and banking constituency, without independently proving current fund employment or a personal cash check. Other similarly named bankers are not assigned portraits or additional biographies without exact identity corroboration.

Luc Philips is identified by KU Leuven’s2000 GFF article as a director representing Almanij-KBC. This public historical board affiliation is distinguished from the fund’s current official directors. No present fund employment, personal cash investment, education or biography from an unrelated same-name person is inferred.

Olivier Lescroart is named a GFF advisory committee member representing KU Leuven in the university’s2000 article. The university’s own2001 technology-transfer reporting identifies him as a Technology Transfer Officer involved in patent licensing. These are dated university/fund affiliations and do not establish a current corporate GFF officer or employee role.

Tony Pilozzi is named a GFF director representing VIV-Fortis in KU Leuven’s2000 published board roster. This is historical governance of the original fund initiative, not a current managing-partner or executive appointment in the present evergreen legal company. No personal investment is inferred.

Martin Hinoul is named GFF’s managing director and an advisory committee member representing KU Leuven in the university’s2000 fund article. His own Crowdsourcing Week speaker biography describes a KU Leuven physics doctorate, postgraduate business training and research-region business development. Historical fund management is not asserted as a current appointment; the latest registry instead names Rudi Cuyvers managing director.

Caroline Rassell is listed by Parkinson’s UK as Chief Executive. Own published biography: "I am proud to be the CEO of Parkinson's UK whose relentless drive is to listen, work with and be guided by the Parkinson's community. The charity's core purpose is to provide care, hope, better treatments and ultimately a cure. "I have the privilege of being in a position where I can connect with people affected by Parkinson's and listen to and learn from their experience to ensure that the charity is delivering what they view as important. I also have the great honour of being in a position to say thank you to the many people and organisations who support the charity to ensure that we have the resources to deliver our offer. "My background of being a CEO in the NHS and having started my career in local government allows me to bring the learning and connections from those roles into my current position. "I care passionately about end of life care and as such I am trustee of my local hospice. "Being active is also something that I believe strongly in, as it's great for your physical and mental health and allows you to make new and different connections. I am an avid and proud parkrunner and have now graduated onto collecting parkruns to spell both my name and the letters of the alphabet." Photo of Caroline by Public Finance/Redactive Publishing.

Parkinson’s UK is the operating name of the Parkinson’s Disease Society of the United Kingdom, an independent UK charity supporting people affected by Parkinson’s disease, influencing care and funding research into neurodegeneration and treatments. Exact charitable company 00948776, registered charity England/Wales258197 and ScotlandSC037554; current registered office50Broadway,LondonSW1H0DB. Founded1969. Its research funding includes academic grants and the Parkinson’s Research Ventures drug-development programme, formerly Parkinson’s Virtual Biotech, run in partnership with the Parkinson’s Foundation. These are neuroscience and translational drug-discovery activities, not evidence that every project uses AI or has regulatory approval. Its wholly owned Parkinson’s Research Ventures Limited (11228595, incorporated2018) is a separate investment subsidiary. The group annual2025 accounts identify EndLyz research investments/convertible loan arrangements, separately from the charity’s intercompany loan to its subsidiary. May2026 programme literature reports overGBP33million committed to research; this is a cumulative programme commitment, not an external LP fund closing, paid company capital or current AUM. The current own leadership pages publish six executives and thirteen trustees; their generic executive-page count is stale. Registry additionally confirms trustee KristinaMurrin appointedSeptember1,2026 and secretaryJudethNeville. GaryShaughnessy remains Chair in the published directory, while a June2026 announcement schedules Kristina’s chair handover forOctober2026 without an exact day; no completed handover is assumed. Formal honorary president/patron and recently departed leaders are qualified separately. Research project commitments, reported fair values and announced follow-on commitments are not automatically paid equity tickets.

Graziano Lolli serves as Scientific co-founder at Sibylla Biotech. Scientific co-founder with protein chemistry, structural biology and drug-discovery experience across industry and academia, including Trento kinase/bromodomain research.

Pietro Faccioli serves as Scientific co-founder at Sibylla Biotech. Scientific co-founder and physicist with Stony Brook doctorate; developed computational methods for protein conformational transitions at Trento and INFN.

Maria Letizia Barreca serves as Scientific co-founder at Sibylla Biotech. Scientific co-founder and medicinal-chemistry researcher whose work includes computational discovery for infectious, neurodegenerative and inflammatory disease.

Emiliano Biasini serves as Scientific co-founder at Sibylla Biotech. Scientific co-founder and neurodegeneration researcher with prior Washington University, Mario Negri and Boston University research, followed by Trento protein-aggregation work.

Lorenzo Alibrandi serves as Corporate Development at Sibylla Biotech. Corporate-development professional with Tor Vergata and IE Business School education, prior venture and startup-advisory work at Lumen Ventures and Alea Consulting. Own popup contains the heading typo Abrandi; current card establishes Alibrandi.

Zhasmine Mirzoyan serves as Lab Manager at Sibylla Biotech. Biologist with Ben-Gurion graduate training and Ulm doctorate; postdoctoral work in Milan and Trento investigated metabolism and inflammation using Drosophila.

Federico Carati serves as Technician at Sibylla Biotech. Insubria-trained industrial/molecular biotechnologist with ZHAW fibroblast-screening research and San Raffaele lentiviral gene-therapy experience.

Marta Pandini serves as Senior Scientist at Sibylla Biotech. Milan pharmaceutical-chemistry graduate with2023 Humanitas experimental/molecular-medicine doctorate, earlier Candiolo and Nerviano cancer research.

Laura Raggi serves as Senior Scientist at Sibylla Biotech. Perugia/Turin-trained biotechnologist with2024 Bicocca doctorate and San Raffaele gene-therapy-institute research on hematopoietic stem-cell niches.

Clorinda Bello serves as Senior Technician at Sibylla Biotech. Milan-Bicocca-trained biologist with neural-stem-cell and preclinical CNS research, plus cell-processing experience for transplantation.

Giulia Frapporti serves as Senior Scientist at Sibylla Biotech. Ferrara-trained pharmaceutical chemist with Trento biomolecular-sciences doctorate. Earlier research covered dopamine receptors, Parkinson-related proteins and autophagy.

Roberta Gioia serves as Senior Scientist at Sibylla Biotech. Roma Tre biology graduate with2021 Sapienza cell/developmental-biology doctorate and Trento neurogenesis and neuropsychiatric-protein research.

Laura Copat serves as Lead Technician at Sibylla Biotech. Trento and Verona-trained molecular/medical biotechnologist with experimental research on prion-protein folding-interference degraders.

Serena Bonifati serves as Head of Assay Biology at Sibylla Biotech. Cancer-biologist and virologist with2014 DKFZ doctorate and Ohio State postdoctoral research into retroviral and innate-immune mechanisms.

Alessandro Galbiati serves as Director of Biology at Sibylla Biotech. Milan-Bicocca biotechnology graduate with IFOM molecular-medicine doctorate, prior AstraZeneca, Artios and Nerviano discovery work. Own biography dates Sibylla biology leadership from January2026.

Simone Lanfredini serves as Head of In vivo Pharmacology at Sibylla Biotech. Turin-trained biotechnologist with clinical/experimental-medicine doctorate and cancer-model research at Cardiff and Oxford.

Fabiana Russo serves as Staff Scientist at Sibylla Biotech. Medicinal chemist whose published biography describes Modena/Reggio Emilia doctoral research in synthetic and analytical methods for pharmaceutical compounds.

Leda Bencheva serves as Principal Scientist at Sibylla Biotech. Modena/Reggio Emilia-trained medicinal chemist with doctorate in bioactive-molecule synthesis and experience in synthetic chemistry, drug metabolism and patents.

Gianluca Papeo serves as Head of Medicinal Chemistry Development Lab at Sibylla Biotech. Pharmacy-trained medicinal chemist with Milan synthesis specialization and Nerviano drug-discovery leadership, including oncology and PARP inhibitor research.

Alberto Balacco serves as Lab Technician at Sibylla Biotech. Milan chemistry graduate with polymer-characterization and Ronzoni Institute spectroscopy experience. Supports compound management and laboratory operations.

Emilia Cassese serves as Staff Scientist at Sibylla Biotech. Naples Federico II pharmaceutical-chemistry graduate whose prior fellowships investigated coronavirus inhibitors and HDAC6 inhibitors for cystic fibrosis.

Irina Stefanelli serves as Staff Scientist at Sibylla Biotech. Naples Federico II-trained pharmaceutical chemist with a2022 doctorate and antiviral/peptide discovery research. Detailed biography spelling Stefanelli resolves the card typo Stefanellli.

Carmine Varricchio serves as Principal Scientist at Sibylla Biotech. Siena-trained pharmaceutical chemist with Cardiff doctoral research and earlier IRBM medicinal-chemistry experience, including mitochondrial-dysfunction drug research.

Alexandros Patsilinakos serves as Head of Medicinal Chemistry Discovery Lab at Sibylla Biotech. Sapienza-trained medicinal chemist with pharmaceutical-sciences doctorate and experience in molecular modelling, cheminformatics and machine learning for drug discovery.

Lars Meuser serves as Staff Scientist at Sibylla Biotech. ETH Zürich interdisciplinary-sciences graduate with Cambridge and IBM research experience. His published doctoral research with Milan-Bicocca/Sibylla explores quantum-computing methods for discovery; this is research, not demonstrated clinical benefit.

Cristina Risueño Fernández serves as Staff Scientist at Sibylla Biotech. Spanish-trained biotechnologist with a2021 molecular-biology/biomedicine doctorate from the University of the Basque Country; studies protein biophysics and molecular simulations.

Cassiano Langini serves as Senior Scientist at Sibylla Biotech. Engineering-physics graduate from Milan Polytechnic and Zurich-trained biomolecular researcher, with molecular-dynamics and docking-software research.

Enrica Colasurdo serves as Head of Computational Lab at Sibylla Biotech. Computational scientist whose own biography describes molecular dynamics and protein-folding research.

Giovanni Spagnolli serves as Co-founder & CTO at Sibylla Biotech. Trento-trained cellular/molecular biotechnologist with biomolecular-sciences doctorate. His doctoral work developed protein-folding intermediate targeting and prion molecular simulations; leads Sibylla research and pipeline development.

Ward Capoen serves as Board member at Sibylla Biotech. A V-Bio investor who joined in2016 after molecular-biology research and biotechnology investment analysis at Candriam. Holds Ghent biotechnology doctorate and Vlerick MBA.

Roberto dalla Marina serves as Board member at Sibylla Biotech. Physics-trained investor and technology-transfer executive with research and management experience at CERN, CSEM, Colibrys and Olivetti, and subsequent venture and innovation leadership. His doctorate is from ETH Zürich. Directory card spelling Della Marina and detailed biography dalla Marina refer to the same person. Technology-transfer Partner at Vertis and investment-committee member for Vertis Venture 3 Technology Transfer; also Managing Partner at Obloo. Previously led AlAdInn Ventures and held innovation, biomedical-cluster and research-infrastructure leadership roles. Trained in physics at Trieste and earned his doctorate at ETH Zurich. Vertis prints Della Marina while Sibylla uses dalla Marina; the matching career and education identify the same person.

Marianne Bjordal serves as Board member at Sibylla Biotech. Joined3B Future Health in2018 and became partner in2022. Previously researched at CNRS; holds Bergen molecular-biology education, a Nice doctorate and MBA. Marianne Bjordal joined 3B Future Health Fund in 2018 and became a partner in 2022. She combines biotechnology research and early-stage investment experience, including prior CNRS work. Her education includes molecular biology at Bergen, a molecular and cellular biology doctorate at Nice and an MBA. Her existing Sibylla board role and authentic portrait are preserved.

Lidia Pieri serves as Co-founder & CEO and Board Member at Sibylla Biotech. A physicist and executive who helped found Sibylla in2017. Her education includes a Rome Tre theoretical-physics doctorate and MIB executive MBA; prior research covered astrophysics and computational biophysics. The EUR25.4M fundraising figure in her biography is cumulative.

Dieter Weinand serves as Chairman at Sibylla Biotech. Previously led Bayer Pharma and held pharmaceutical commercial and strategic leadership roles at Pfizer, Bristol Myers Squibb and Otsuka.

Sibylla Biotech S.p.A. is an Italian preclinical drug-discovery company founded in2017 from interdisciplinary protein-folding research associated with Trento, Perugia, INFN and Telethon. Its PPI-FIT platform models transient protein-folding intermediates to identify small-molecule Fold Interfering Degraders. Its Oneiros platform explicitly applies machine learning to pocket discovery and molecular optimization. CNS discovery collaborations with Takeda and Ono are research partnerships; undisclosed commercial fees and milestones are not treated as equity funding or realized cash. Therapeutic effects remain investigational, without verified clinical approval or efficacy. Current own directory publishes35 distinct people across board, executives, computational science, medicinal chemistry, biology, business development and scientific founders. Exact legal footer identifies VAT/register04514620238 and Bresso laboratories; historical S.r.l. and current S.p.A. are the same source-qualified operating company. Nominal share capital EUR187758.17 is not counted as financing. Actual disclosed equity funding is EUR2.4M initial investment announced October14,2019 and EUR23M Series A closed October4,2022; the CEO’s EUR25.4M figure is cumulative, not a third round.

Raf Moons is the permanent representative of BNP Paribas Fortis Private Equity Management NV (enterprise0438.091.788), a corporate director of GFF, registered fromMarch8,2016. Private Capital Belgium’s own director biography identifies him as Head of BNP Paribas Fortis Private Equity, with a KU Leuven physics doctorate and Vlerick MBA, earlier Imec research/business-development work and Fortis investment experience from1999. The permanent representative is distinguished from the corporate director; no personal investment is inferred. Raf Moons is publicly documented as Head of Private Equity within the BNP Paribas Fortis Private Equity platform. This specifically scoped public affiliation is distinct from a personal cash investment or a parentbank investment check.

Raf Spinoy is a GFF director registered fromDecember1,2016 in the official Belgian entity record reviewedOctober2026. The primary record establishes his exact fund-board affiliation but does not publish an individual biography, portrait or separate manager/executive title. Municipal or other same-name people are not merged without identity proof.

Tim Derycke is a GFF director registered fromJanuary1,2026. KBC Securities’ own current Investment Services page names him Head of Investment Services and publishes his authentic named portrait. GFF legal board service is distinct from his bank role; it does not establish a personal cash investment or an independently disclosed GFF partnership title.

Isabelle Cardinael is a current GFF director, registered sinceApril17,2013. The2015 Royal Flemish Academy speaker biography identifies her as a KBC Securities investment manager representing KBC Bank on university and microfinance fund boards, after correspondent banking and real-estate financing roles. Her current self profile lists KBC Private Partners Climate Technologies RI; this background is not converted into an invented GFF employee or managing partner title.

Quinn Lavin is listed by Samsara BioCapital as Administrative Office Assistant. She joined inJanuary2024 to provide office and administrative support to investment and operating leaders.

Ana Mariategue is listed by Samsara BioCapital as Exec Assistant. She joined in2018 and provides executive, administrative and operational support.

Noushin Vaccani is listed by Samsara BioCapital as Exec Assistant/Operations Manager. She joined at the2017fundlaunch and provides administrative and operational support to the investment team.

Meysis Lam is listed by Samsara BioCapital as Accounting Supervisor – Portfolio. She joined inSeptember2021 and manages portfolio-company accounting and financial reporting.

Connie Su is listed by Samsara BioCapital as Senior Fund Accountant. She joined in2026 to support fund accounting, financial reporting and operations.

Rita Ann Gomez is listed by Samsara BioCapital as Senior Fund Accountant. She joined in2026 after fund-accounting work at Standish and eight years at EY, supporting investment-fund financial reporting.

Marie Chang is listed by Samsara BioCapital as Associate Director, Finance. She joined inNovember2022 and manages accounting and financial reporting for the management company.

Andrew Walker is listed by Samsara BioCapital as Assistant Controller. He joined in2023 after fund-administration work at GenII, bringing private-equity accounting and reporting experience.

Indrani Rebbapragada is listed by Samsara BioCapital as Sr. Dir Project & Portfolio Management. She joined in2022 and directs project and portfolio-management support. Earlier work includes biotechnology program-management and research roles.

Riki Harada is listed by Samsara BioCapital as Vice President of Finance. He joined in2023 after fund-controller work at LogosCapital and other investment-operations responsibilities.

Carolyn Nguyen is listed by Samsara BioCapital as Deputy General Counsel. She joined in2025 and supports investment, fund-compliance and regulatory legal work after advising life-sciences businesses and investors at international law firms.

Gemma Frisius Fund (GFF), known in Dutch as Gemma Frisius-Fonds KU Leuven, is an evergreen seed-capital investment company supporting research-based university spin-offs and selected KU Leuven student ventures. The initiative was founded in1997 as a joint venture of KU Leuven, KBC and the predecessor of BNP Paribas Fortis Private Equity Belgium; its operation is closely linked to KU Leuven Research & Development (LRD). The current Belgian legal entity is GEMMA FRISIUS-FONDS KU LEUVEN NV, enterprise0477.960.372, registered from July10,2002 with current legal name from January22,2021. It absorbed the original1997 NV, enterprise0461.734.351, on December16,2009. These related legal vehicles are distinguished from KU Leuven’s separate statutory university and other bank-managed funds. GFF invests in exchange for equity and supports portfolio companies through business planning, networks and board participation, without a fixed technology restriction. Its public portfolio includes AI and analytics, semiconductors, diagnostics, neurological drug discovery and research-based materials and clean technologies. Examples of relevant research-based companies named in the university’s own GFF portfolio are reMYND, Augustine Therapeutics, CoMoveIT, RunEASI, Aspect Analytics, ArtiQ, Magics Technologies and Pulsify Medical. Portfolio affiliation does not by itself disclose round date, investment ticket or current unexited ownership. The VLAIO January2026 entry reports an evergreen fund size ofEUR55million and typical minority-equity tickets125000–1250000EUR; these are programme size and investment ranges, not a newly verified LP fund closing or actual allocation to an individual company. The official registry separately reportsEUR20.5million registered capital for the current NV andEUR16.395million for its merged predecessor; registered capital is not a new fund cash close. GFF also supports eligible KICK student ventures with convertible loans up toEUR20000, a maximum mechanism rather than proof of a specific award. Current legal directors/representatives and historically published board/advisory affiliations are separately qualified; a corporate shareholder/director is not silently substituted by an individual or merged with the university parent.

Kelly Tomera is listed by Samsara BioCapital as Vice President of Investor Relations & Marketing. She joined in2026 after product and go-to-market leadership at Visa, bringing commercial strategy experience to investor communications.

Patrick Dominguez is listed by Samsara BioCapital as Chief Compliance Officer. He joined in2026 after compliance leadership at ACA, Hg and VectorCapital. He supports regulatory programs for investment management.

Liz Grace is listed by Samsara BioCapital as Partner and Head of Investor Relations & Marketing. She joined in2025 to lead investor communications and marketing after investor-relations work at healthcare investment manager Redmile.

Reena Jashnani-Slusarz is listed by Samsara BioCapital as Strategic Advisor. She advises the platform after legal and operating leadership in investment management, including law-firm and in-house work.

Dolca Thomas is listed by Samsara BioCapital as Senior Advisor. A physician-scientist and immunologist, she advises programs using experience from academia, pharmaceuticals and biotechnology.

Dan Spiegelman is listed by Samsara BioCapital as Venture Partner. He joined in2023 and helps portfolio businesses with financial strategy, planning, execution and preparations for public markets.

Stephen Shuttleworth is listed by Samsara BioCapital as Venture Partner. He joined in2019 after pharmaceutical-science work in the UK, US and Canada, contributing drug-discovery and development expertise.

Guna Rajagopal is listed by Samsara BioCapital as Venture Partner. He joined in2022 and applies informatics, analytics and computational methods across drug discovery and development.

John Orwin is listed by Samsara BioCapital as Venture Partner. He joined in2024 after senior operating roles across biotechnology and pharmaceutical businesses.

Marcos Milla is listed by Samsara BioCapital as Venture Partner. He advises drug-discovery programs across immunology, neurosciences, pain and oncology.

Alan Eisenberg is listed by Samsara BioCapital as Venture Partner. He joined in2024 and supports portfolio businesses with biotechnology operational and program-development expertise.

Keith Gottesdiener is listed by Samsara BioCapital as Venture Partner. His career spans academic medicine, pharmaceutical research and leadership of publicly traded biotechnology businesses.

Eric Dobmeier is listed by Samsara BioCapital as Venture Partner. He joined in2024 with operating, business-development and corporate-leadership experience in biotechnology.

Thomas F. Bumol is listed by Samsara BioCapital as Venture Partner. He joined inJanuary2026 after biotechnology and immunology research leadership at EliLilly and subsequent scientific leadership work. He brings experience building biologic-drug programs.

Robert Stein is listed by Samsara BioCapital as Venture Partner. He joined in2018 after pharmaceutical discovery and development leadership at Merck, Ligand, Incyte, Roche and Agenus. He holds medical and pharmacology doctoral qualifications.

Betsy Santos is listed by Samsara BioCapital as Venture Partner, Chief People Officer. She joined in2022 and leads internal human resources while advising portfolio businesses on people management and leadership. Earlier HR experience includes CVTherapeutics, Cepheid and Genentech.

David Parry is listed by Samsara BioCapital as Venture Partner. He joined in2021 after immunology-focused business-development and due-diligence work at GSK.

Jim P. Edwards is listed by Samsara BioCapital as Venture Partner. He joined in2022 after a drug-discovery career across several therapeutic fields, bringing scientific development experience to portfolio businesses.

Ehi Akhirome is listed by Samsara BioCapital as Senior Associate. He joined in2026 after healthcare investing at Norwest and consulting at McKinsey. His medical and developmental-biology training supports biotechnology and diagnostics evaluation.

Clara Dong is listed by Samsara BioCapital as Senior Associate. She joined in2026 to invest in public biotechnology after equity research at Jefferies and earlier exposure at EagleHealth. Her doctoral research involved biomedical materials and therapeutic delivery.

Jake Bieber-Dishart is listed by Samsara BioCapital as Senior Associate. He joined in2025 and serves as an observer on AgniBio and MaroBio boards, supporting scientific and investment evaluation.

Matt Eckler is listed by Samsara BioCapital as Principal, Public Investing. He leads public-equity investing after ArrowMark, GMT and RBC roles. He joined in2025 and has research experience in brain development and neuroscience.

Mike Dybbs is listed by Samsara BioCapital as Partner. Michael Dybbs has been a partner since the fund’s 2017 launch and serves on biotechnology company boards. His work combines scientific evaluation with venture-investment execution.

Previously led AI and analytics at Net Purpose and Babylon Health; focuses on production AI and warehouse operations.

Leads hardware/software integration and technology strategy. Previously led development at IBM, Endava, Digital Science and Just Eat.

Previously CFO and the first employee at Nivoda, following seven years in investment banking.

Insight Partners source, reviewed October 8, 2026: I joined Insight Partners in 2021 to focus on high-growth software businesses across SaaS, DevOps, and infrastructure. Previously, I worked as a seed investor at Primary Venture Partners and growth investor at B Capital Group. Across my investing career, I've been fortunate enough to invest at every stage of a company's growth, from pre-seed to pre-IPO, and it is clear that the team is always what matters most. Before I became an investor, I worked in go-to-market roles at three B2B startups. My innate extroversion, empathy, and curious mind were a natural fit for customer-facing roles where I could truly understand their problems and come up with solutions for how to solve them. My time working at two developer platforms (one of which was an Insight portfolio company!) taught me the importance of being creative and efficient — traits that were the embodiment of the best engineers. Working at a distributed open-source company showed me the power of community and how great ideas can come from anywhere. This inspired me to start a podcast show in grad school called 52 Founders to uncover the psychology behind entrepreneurship. Though each entrepreneur had a different story to tell, the common themes were perseverance and being unafraid of failure. Outside of work, I am typically planning my next big adventure around the world or immersing myself in fictional ones, whether reading a SciFi series or seeing the latest Marvel movie. Verified name bridge: Exact Filigran primary board calls her Crissy Costa Behrens and Insight Principal; Insight own Crissy Behrens profile lists Filigran partnership, the same software-investing career and board relationship. Preserve original canonical full-name person and board role; current Insight MD versus issuer older Principal not silently overwritten.

Previously conducted ransomware, OSINT and dark-web investigations at XMCO’s CERT.

Previously led cyber threat-intelligence analysis teams at ANSSI and helped develop OpenCTI.

Leads engineering and architecture across Filigran’s open-source threat-management products.

Previously worked in cyber threat intelligence at CERT-EU and Naval Group.

Previously worked on strategic partnerships at Google and product development at Telefónica.

Previously led cyber threat intelligence in the French public sector, where OpenCTI originated.

Previously Chief Revenue Officer at Finite State and held sales leadership positions at Brinqa and Planview.

Alain Decombe is a corporate and private-equity attorney at Dechert. The firm’s May 2021 announcement identifies him as Paris office leader and Deputy Chair for International Operations; its December 2025 Stago transaction announcement confirms his continuing partner status. His primary firm profile describes an international legal career and extensive healthcare transaction work. Historical leadership titles are time-qualified rather than asserted current. ESSEC Business Angels’ October 2022 announcement explicitly names him as a private DeepLife investor. His personal investment is distinct from legal advice and is not attributed to Dechert. The authentic portrait is extracted unchanged from his named firm-published profile.

Didier Valet is a published Founder and General Partner of European seed-stage venture firm Varsity. The current native directory provides his named portrait and describes his strategic and financial support of founders. His own earlier announcement describes more than 70 angel investments preceding Varsity. ESSEC Business Angels’ October 2022 DeepLife financing announcement explicitly names him as a private investor. That historical personal investment is not assigned to the later Varsity manager or a fund, and its allocation is undisclosed.

Sylvain Gariel co-founded DNA Script in 2014 with Thomas Ybert and Xavier Godron and co-invented its enzymatic DNA synthesis technology. DNA Script’s October 2020 primary release identifies him as COO and an MIT Innovator Under 35 honoree. His published career includes engineering training at Mines Paris and Corps des Mines. These DNA Script operating titles are historical source-confirmed positions; continuation is not inferred from older announcements. The primary October 2022 DeepLife raise names him as a private investor, with undisclosed allocation. His authentic named portrait is published by Institut Choiseul.

Filippo Monteleone founded Careit in 2016 and is its published founding president. His own biography describes almost 30 years of healthcare investment and corporate experience, including 15 years at Ramsay Générale de Santé, where he was Deputy CEO. He began his career at Worms & Cie in 1994 and became Investment Director. The primary October 2022 DeepLife financing announcement explicitly names him as a private investor. His DeepLife investment is not automatically a Careit corporate check, and his allocation is unpublished.

Stéphane Imbert is the founder of LS Group, originally Light & Shadows, established in 2009 to develop virtual-reality and industrial visualization applications. He founded PiXYZ in 2017 and sold it to Unity in 2021. His own company’s June 2023 profile explicitly describes his subsequent financing and support of UVR, Robeauté and DeepLife. The October 2022 ESSEC Business Angels announcement independently names him as a private participant in DeepLife’s EUR 6M financing. His individual allocation is undisclosed; this personal investment is not assigned to LS Group or Unity.

Oncology research and development specialist with prior senior roles at Glaxo-Wellcome and Johnson&Johnson. He contributes to CD3 scientific advisory board; this advisory affiliation does not imply university employment.

Medicinal chemist and research-project consultant with prior AstraZeneca experience across neuroscience,infections,respiratory and inflammatory diseases. Her CD3 biography describes StockholmUniversity doctoral training and NewZealand postdoctoral work. She is an external CD3 scientific adviser.

Drug-discovery consultant with a biology doctorate and earlier lead-discovery and cardiovascular-research leadership at Bayer, followed by a CSO role at Axxam. He advises CD3 scientific programmes as an external scientific-advisory-board member.

European Investment Fund investment manager focused on European venture funds, with earlier banking and financial-services experience. She holds finance degrees and the CFA designation and serves on CD3 investment committee. This is an external institutional committee affiliation.

Life-sciences commercialization adviser and company chair. Former STORM Therapeutics CEO and CancerResearchTechnology executive; he helped develop academic drug-discovery partnerships and the CRT Pioneer Fund. CD3 identifies him as an investment-committee member.

Early-stage life-sciences investor and technology-transfer specialist. He founded SixthElementCapital and developed the CRT Pioneer Fund after earlier work at CancerResearchCampaignTechnology and Prelude. His CD3 investment-committee affiliation is separate from university employment.

Life-sciences executive with venture-investment and pharmaceutical partnership experience. Her CD3 biography describes earlier work at Organon,NovoHoldings,Chiesi and CreditSuisse, and an Oxford doctorate. CD3 committee affiliation is separate from institutional employment.

CD3 business-development leader since2011, with earlier life-sciences commercialization and corporate-finance roles at GlaxoSmithKline,Fortis and Kiadis. He studied bioengineering at KU Leuven and management in Brussels.

Medicinal chemist leading CD3 medicinal-chemistry operations. His career includes organic-chemistry doctoral research, KU Leuven Rega Institute postdoctoral work and medicinal-chemistry roles at4AZA and PierreFabre; he joined CISTIM in2007.

Drug-discovery investment leader and European patent attorney. He has led CD3 since its2006 inception, previously managed pharmaceutical intellectual property at KU Leuven Research & Development and holds a pharmaceutical-sciences doctorate from KU Leuven.

Head of Spin-off and Innovation within KU Leuven Research&Development, supporting commercialization of university research and new technology businesses. Current university organizational and person directories confirm this internal unit leadership.

KU Leuven professor of innovation management and current executive director of its internal Research&Development technology-transfer unit. He chairs the separately incorporated KU Leuven Association. His former university managing-director position is historical; current university managing director is WimDesmet.

Professor Margriet Van Bael (*1972) is a professor in experimental solid state physics and has served as vice dean for education at the Faculty of Science since 2022. Policy Team2025–2029 responsibilities: Artificial Intelligence.

Professor Tom Van Puyenbroeck (*1969) has been academic director of the Brussels campuses since 2020. Policy Team2025–2029 responsibilities: Alumni and Emeritus Professors.

KU Leuven managing director and mechanical-engineering professor working on mechatronic system dynamics. The university directory also identifies his affiliations with Leuven.AI and physics-based modeling for in-silico health.

Asiana Fund is the Mumbai investment platform sponsored by Jalaj Dani and rooted in the Dani family’s business network. It backs technology-led and product-led Indian businesses across early, growth and listed stages, including robotics, drones, medical technology, infrastructure and industrial companies. Its investment team and advisers help founders with strategy, governance, operating improvements and international growth. Its Category II AIF platform includes a broad patient-capital first scheme and an advanced manufacturing and innovation second scheme co-sponsored with Taiwan’s JC Capital.

JC Capital Taiwan is a venture-investment platform backing semiconductor, artificial-intelligence, healthcare, clean-technology and renewable-energy businesses. Its investment team helps founders develop product and technology roadmaps, commercialize engineering-intensive technology and build supply-chain partnerships with corporate investors in Taiwan, the United States, Japan and the wider Indo-Pacific region. The Taiwanese fund-management company is a joint venture involving JC Capital Ltd. and Taiwan Cooperative’s venture-capital business. The JC Capital platform co-sponsors an India-focused advanced manufacturing and innovation vehicle with Asiana.

Leads Asiana’s strategy and operational improvement work, drawing on supply-chain and business-transformation experience at Johnson & Johnson and Indian companies.

Oversees compliance and fund operations, including financial reporting, valuation and due diligence. He is a chartered accountant with finance and taxation experience.

Advises Asiana and the Dani Family Office on portfolio building and manufacturing operations. His background includes senior leadership at Asian Paints and Hitech Corporation.

Oversees Asiana’s investments and supports portfolio-company financial strategy, governance and operating improvements. He is a chartered accountant with corporate-finance and investment experience.

Professor Dirk Hermans (*1968) is a professor of clinical psychology and has served as dean of the Faculty of Psychology and Educational Sciences since 2023. Policy Team2025–2029 responsibilities: Libraries and Human Resources.

Professor Evelyne Terryn (*1974) was campus dean of the Faculty of Law and Criminology from 2012 to 2019 and has been a member of the KU Leuven Kulak Campus Council, Management Committee and Executive Committee since 2021. Policy Team2025–2029 responsibilities: Sustainability.

Advises Asiana’s portfolio companies after an international operating career at Asian Paints, including leadership of Asian Paints International.

Professor Isabelle Huys (*1976) has been head of the Clinical Pharmacology and Pharmacotherapy since 2020. Policy Team2025–2029 responsibilities: Impact and Global Development.

Founded and sponsors Asiana Fund and is a co-promoter of Asian Paints. His experience spans business leadership, technology investing and supporting companies such as robotics manufacturer Addverb.

Advises Asiana on strategy, digital transformation and growth. His background includes global leadership at Unilever and Raymond’s lifestyle business.

Invests and supports portfolio companies after investment roles at 360 ONE Asset and Mumbai Angels. Her education includes engineering and business degrees.

Advises Asiana and is chancellor of UC San Diego. His research background includes autonomous robotics, embedded systems and artificial intelligence.

Leads technology investing with a background in semiconductors, embedded systems and product development, including senior leadership at Texas Instruments India.

Invests in technology and connected-device businesses after experience in entrepreneurship, product development and venture-fund management across multiple regions.

Focuses on manufacturing, building materials and technology businesses. His background includes SIDBI Venture Capital, equity research and entrepreneurship, and he is a chartered accountant.

Professor Stefaan Vaes (*1976) is a mathematician. He has been head of the Analysis Division of the Department of Mathematics since 2011, and has chaired Metaforum, KU Leuven’s interdisciplinary think tank, since 2020. Policy Team2025–2029 responsibilities: Culture, Art & Heritage and Human Resources.

Advises Asiana’s portfolio companies on business transformation and operating performance. His career at Asian Paints included manufacturing, sales, supply chains and international business leadership.

KU Leuven is the Belgian nonprofit research university and institutional investor legally named Katholieke Universiteit Leuven, enterprise0419.052.173 and LEI5299001MN2MYAHLGXD65. Its legal office confirms a private-law sui-generis legal personality, registered seat OudeMarkt13,Leuven, and statutory higher-education,research and public-service missions. The institution has a historical Leuven-university tradition commemorated by its600thanniversary in2025; the current legal personality dates from publication of its constituting deed in1970. Foundingyear is therefore left unspecified instead of conflating historic academic foundation and current legal entity. KU Leuven Research&Development(LRD) is its internal technology-transfer unit, not a separate inferred investment firm. It supports research contracts, patents/licensing, spin-off creation and investment. Current public governance is the2025–2029 policy team led by rector SeverineVermeire; stale LucSels biographies do not establish current rectorship. Managing director WimDesmet is distinct from LRD executive director KoenraadDebackere; PaulVanDun leads LRD central management and RudiCuyvers heads Spin-off&Innovation. Institutional AI research includes Leuven.AI, while the LeuvenBrainInstitute coordinates neuroscience. The Centre for Drug Design and Discovery(CD3), formed by LRD and the EuropeanInvestmentFund in2006, combines drug-discovery facilities, scientific expertise and investment in academic projects, spin-offs and biotechnology businesses, including neuroscience. CD3 privacy directs data-controller matters to KU Leuven and Biohaven SEC filings identify KatholiekeUniversiteitLeuven as the counterparty for CD3-developed drug-discovery licences. These support one institution-level profile with explicitly scoped CD3/LRD roles; no separate incorporated CD3 manager or transaction subscriber legal vehicle is asserted without registry proof. CD3 Labs/CISTIM operating-laboratory identities are not automatically merged into the university. CD3 public named leadership includes three management members, five investment-committee members and three external scientific advisers. Such committee/adviser affiliations are distinct from university employment and this scoped directory is not the full university or lab workforce. Primary historical capital comprises EUR8M initialCD3 capital in2006, EUR16M incremental capital in2010 (EUR24M aggregate), EUR60M third fund closed in2016, and EUR70.5M fourth fund closure announced October19,2023. EUR154.5M is their cumulative capital, not another raise; a university page updated December2024 describes the same fourth-fund close. LRD,EIF and GemmaFrisiusFund provided capital for CD3IV; individual commitment allocations and exact paid draws are unpublished. These managed/platform-capital facts are described here rather than misclassified as equity fundraising by the nonprofit university. StructuredInvestmentFund records require an InvestmentFirm owner; the university retains its correct institutional Company type and no false investment-firm duplicate is created merely to bypass that constraint. GemmaFrisiusFund is a separately incorporated university/bank seed-capital joint venture and its checks are not duplicated under KU Leuven. The exact institution is independently named alongside GFF in reMYND financing; EndLyz publicly names KU Leuven/CD3 backing without a disclosed ticket or financing-event allocation. Licensing partnerships and clinical collaborations are not assumed to be cash equity subscriptions.

Adriel Lares is listed as an external senior adviser to DTCP. The directory identifies this adviser’s professional background as Former CFO of Fastly [FSLY :NYSE]. This source-published advisory capacity is distinct from DTCP staff employment and does not prove a personal investment or exact appointment date. Detailed additional career history is not published on this page.

André Christ is listed as an external senior adviser to DTCP. The directory identifies this adviser’s professional background as Co-Founder and General Manager at LeanIX, an SAP company. This source-published advisory capacity is distinct from DTCP staff employment and does not prove a personal investment or exact appointment date. Detailed additional career history is not published on this page.

Braxton Carter is listed as an external senior adviser to DTCP. The directory identifies this adviser’s professional background as Former CFO at T-Mobile [TMUS:NASDAQ]. This source-published advisory capacity is distinct from DTCP staff employment and does not prove a personal investment or exact appointment date. Detailed additional career history is not published on this page.

Dan Thomas is listed as an external senior adviser to DTCP. The directory identifies this adviser’s professional background as CEO of GreenScale. This source-published advisory capacity is distinct from DTCP staff employment and does not prove a personal investment or exact appointment date. Detailed additional career history is not published on this page.

Fotis Karonis is listed as an external senior adviser to DTCP. The directory identifies this adviser’s professional background as Executive Vice President, Capgemini-Altran Group. This source-published advisory capacity is distinct from DTCP staff employment and does not prove a personal investment or exact appointment date. Detailed additional career history is not published on this page.

Gero Decker is listed as an external senior adviser to DTCP. The directory identifies this adviser’s professional background as Co-Founder & General Manager Signavio, an SAP company. This source-published advisory capacity is distinct from DTCP staff employment and does not prove a personal investment or exact appointment date. Detailed additional career history is not published on this page.

Co-founder and former CEO of Affirmed Networks, acquired by Microsoft, and published DTCP senior adviser. Legally and professionally distinct from the same-name respond.io co-founder.

Jean-François Berche is listed as an external senior adviser to DTCP. The directory identifies this adviser’s professional background as CTO of GreenScale. This source-published advisory capacity is distinct from DTCP staff employment and does not prove a personal investment or exact appointment date. Detailed additional career history is not published on this page.

Lars Hinrichs is listed as an external senior adviser to DTCP. The directory identifies this adviser’s professional background as Founder and former CEO of XING. This source-published advisory capacity is distinct from DTCP staff employment and does not prove a personal investment or exact appointment date. Detailed additional career history is not published on this page.

Liam Newcombe is listed as an external senior adviser to DTCP. The directory identifies this adviser’s professional background as SVP Product Energy Strategy & Innovation of GreenScale. This source-published advisory capacity is distinct from DTCP staff employment and does not prove a personal investment or exact appointment date. Detailed additional career history is not published on this page.

Oliver Menzel is listed as an external senior adviser to DTCP. The directory identifies this adviser’s professional background as CEO and Founder of maincubes. This source-published advisory capacity is distinct from DTCP staff employment and does not prove a personal investment or exact appointment date. Detailed additional career history is not published on this page.

Orna Berry is listed as an external senior adviser to DTCP. The directory identifies this adviser’s professional background as Entrepreneur, Scientist, Policy Maker and Industry Executive. This source-published advisory capacity is distinct from DTCP staff employment and does not prove a personal investment or exact appointment date. Detailed additional career history is not published on this page.

Professor Patrick Callaerts (*1964) has been department chair of the Department of Human Genetics since 2020. Policy Team2025–2029 responsibilities: Administrative Simplification & Governance and Human Resources.

Reut Yair is listed by DTCP as Office Manager in its Platform directory. Manages the Israel office after insurance-sector legal work and an El Al flight-attendant role; holds a law degree. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Professor Severine Vermeire has been research coordinator of the Biomedical Sciences Group since 2020 and was previously chair of the Department of Chronic Diseases, Metabolism and Aging. Policy Team2025–2029 responsibilities: International Relations and Wellbeing.

Thorsten Langheim is listed as an external senior adviser to DTCP. The directory identifies this adviser’s professional background as Board Member of Deutsche Telekom. This source-published advisory capacity is distinct from DTCP staff employment and does not prove a personal investment or exact appointment date. Detailed additional career history is not published on this page.

Tim Höttges is listed as an external senior adviser to DTCP. The directory identifies this adviser’s professional background as CEO of Deutsche Telekom. This source-published advisory capacity is distinct from DTCP staff employment and does not prove a personal investment or exact appointment date. Detailed additional career history is not published on this page.

Tom Zapke is listed by DTCP as Analyst in its Infra directory. Works in infrastructure analysis after investment-banking experience at Goldman Sachs, Deutsche Bank and Rothschild; studied business and finance at St Gallen. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Trevor Healy is listed as an external senior adviser to DTCP. The directory identifies this adviser’s professional background as Managing Partner, Sansa Advisors. This source-published advisory capacity is distinct from DTCP staff employment and does not prove a personal investment or exact appointment date. Detailed additional career history is not published on this page.

Uwe Nickl is listed as an external senior adviser to DTCP. The directory identifies this adviser’s professional background as Former CEO, Deutsche Glasfaser Unternehmensgruppe. This source-published advisory capacity is distinct from DTCP staff employment and does not prove a personal investment or exact appointment date. Detailed additional career history is not published on this page.

Carolin Wieczorek is listed by DTCP as Office Manager and Team Assistant in its Platform directory. Supports the Frankfurt office after law-firm partner assistance and consulting-firm administration; trained in specialised translation. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Agata Jaszczura is listed by DTCP as Associate in its Infra directory. Works in infrastructure investing after Deutsche Bank transaction experience, including the Springer Nature listing. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Alice McKay is listed by DTCP as Personal Assistant in its Platform directory. Supports founder Vicente Vento, following investment-team assistance at Alcuin Capital Partners and HR work at Redburn Atlantic. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Alicia Taylor is listed by DTCP as Manager People Operations in its Platform directory. Works on people operations after HR and organisational responsibilities at a translation-technology business. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Alvaro Ramos is listed by DTCP as Senior Manager Portfolio Controlling in its Platform directory. Works on portfolio controlling in Luxembourg after private-equity and property audit experience at EY. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Amber Reid is listed by DTCP as Vice President in its Infra directory. Works in infrastructure investing after transaction advisory at Mazars and digital-infrastructure investment work at Digital9. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Ann-Sofie Kusch is listed by DTCP as Manager Legal in its Platform directory. Works in legal administration and AML compliance, with law studies at Greifswald and earlier paralegal experience. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Anselm Maur is listed by DTCP as Managing Director in its Infra directory. Works on infrastructure transactions and portfolio oversight, following M&A and capital-markets experience at Barclays. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Antonella Imparato is listed by DTCP as Executive Assistant in its Platform directory. Supports Ole Aguirre and Marianne Karlsen, following London executive-assistance and office-management work across investing and corporate businesses. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Arpita Chakraborty is listed by DTCP as IT Operations Manager in its Platform directory. Handles technology operations, vendors, security and compliance, with experience in life sciences and financial services. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Arvind Vurakaranam is listed by DTCP as Associate in its Infra directory. Works on infrastructure deals and portfolio oversight after M&A and technology-telecom investment banking at Bank of America. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Bart de Jong is listed by DTCP as Managing Director in its Infra directory. Works on infrastructure investments and portfolio development, following roles at OMERS Infrastructure and PGGM Investments. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Christiane Repenning is listed by DTCP as Executive Assistant in its Platform directory. Supports senior management following family-office executive assistance and corporate-communications work. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Christoph Steffens is listed by DTCP as Operating Partner in its Infra directory. Supports infrastructure portfolio operations, including finance, organisation, technology systems and expansion, with decades of telecom and technology operating experience. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Claudius Laskawy is listed by DTCP as Principal in its Defence directory. Works on defence investments after innovation advisory roles at Plug and Play and Infront. Directory heading says Principal while its biography says Vice President; exact current rank is inconsistent in own sources. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Dean Shahar is listed by DTCP as Managing Director in its Growth directory. Leads Israeli growth investing in cybersecurity and AI, following Poalim Equity and investment-banking work at Morgan Stanley and Oppenheimer. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Filippo Vidoni is listed by DTCP as Analyst in its Defence directory. Works on defence investments after private-equity experience at I Squared Capital, Columna Capital and Trilantic Europe. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Georgia Watson is listed by DTCP as Partner in its Defence directory. Works on European defence and security investments from London after growth-investing leadership at Lakestar. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Heike Schackmann is listed by DTCP as Manager Finance in its Platform directory. Works in Luxembourg finance after Vistra financial-management work and audit roles at KPMG and BDO. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Iryna Doroshenko is listed by DTCP as Director Fund Management in its Infra directory. Coordinates infrastructure fund transactions, service providers, asset-value calculations and investor reporting. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Jan-Michael Dierkes is listed by DTCP as Managing Director, GC and Head of ESG in its Platform directory. Leads Luxembourg operations, legal work and ESG; earlier responsibilities at K+S included corporate development, transactions and regulation. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Jessica Boyens is listed by DTCP as Vice President in its Infra directory. Works in infrastructure investments; her previous roles include UBS investment banking and CapVest private-equity transactions in London. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Joanna Kwak is listed by DTCP as Manager Capital Formation Real Assets in its Infra directory. Works on real-assets investor relations and fundraising, following investor-relations and capital-markets responsibilities at Pepco Group. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Joe Kanner is listed by DTCP as Associate in its Growth directory. Works in the growth team after supporting investment evaluation and portfolio development at Hanaco Ventures. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Joel-Oskar Raisanen is listed by DTCP as Principal in its Defence directory. Works on defence investments, with technology-investing experience spanning sourcing, transaction execution, portfolio work and fundraising. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Johannes Hausmann is listed by DTCP as Associate in its Growth directory. Works on growth investments after early-stage and growth-fund internships; studied business at St Gallen and EBS. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Jonas Byok is listed by DTCP as Analyst in its Defence directory. Works on defence investments after German military service, with earlier strategy and restructuring experience at Henkel and Roland Berger. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Jonas Janssen is listed by DTCP as Managing Director in its Growth directory. Focuses on European software and AI investing. Current directory heading says Managing Director, while its biography still calls him Principal; that public inconsistency remains qualified. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Jonli Keshavarz is listed by DTCP as Analyst in its Growth directory. Works in growth investing after early venture experience at Rothenberg Ventures and investment analysis at Cartography Capital. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Julius Carle is listed by DTCP as Vice President in its Infra directory. Works on infrastructure origination and portfolio management, following transaction experience at Lazard and Deutsche Telekom. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Karl Hinn is listed by DTCP as Senior Legal Counsel in its Platform directory. Advises on fund structures and regulation, following investment-management legal work at Arendt & Medernach; admitted in Germany, Luxembourg and New York. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Krishnan Patel is listed by DTCP as Head of Investor Relations, DTCP Growth in its Growth directory. Leads growth-strategy fundraising and investor relationships, following private-fund responsibilities at Molten Ventures and earlier Apax and Moelis roles. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.